Clostridium perfringens enterotoxin (CPE), a major cause of food poisoning, forms physical pores in the plasma membrane of intestinal epithelial cells. The ability of CPE to recognize the epithelium is due to the C-terminal binding domain, which binds to a specific motif on the second extracellular loop of tight junction proteins known as claudins. The interaction between claudins and CPE plays a key role in mediating CPE toxicity by facilitating pore formation and by promoting tight junction disassembly. Recently, the ability of CPE to distinguish between specific claudins has been used to develop tools for studying roles for claudins in epithelial barrier function. Moreover, the high affinity of CPE to selected claudins makes CPE a useful platform for targeted drug delivery to tumors expressing these claudins.
References
[1]
Sakurai, J.; Nagahama, M.; Ochi, S. Major Toxins of Clostridium perfringens. Toxin Rev.？1997, 16, 195–214.
McClane, B.A. Clostridium perfringens enterotoxin acts by producing small molecule permeability alterations in plasma membranes. Toxicology？1994, 87, 43–67.
[4]
Koval, M. Claudins: Key pieces in the tight junction puzzle. Cell Commun. Adhes.？2006, 13, 127–138.
[5]
Angelow, S.; Ahlstrom, R.; Yu, A.S. Biology of claudins. Am. J. Physiol. Renal Physiol.？2008, 295, F867–F876.
[6]
Anderson, J.M.; Van Itallie, C.M. Physiology and function of the tight junction. Cold Spring Harb. Perspect. Biol.？2009, 1, a002584.
[7]
Katahira, J.; Sugiyama, H.; Inoue, N.; Horiguchi, Y.; Matsuda, M.; Sugimoto, N. Clostridium perfringens enterotoxin utilizes two structurally related membrane proteins as functional receptors in vivo. J. Biol. Chem.？1997, 272, 26652–26658.
[8]
Katahira, J.; Inoue, N.; Horiguchi, Y.; Matsuda, M.; Sugimoto, N. Molecular cloning and functional characterization of the receptor for Clostridium perfringens enterotoxin. J. Cell. Biol.？1997, 136, 1239–1247.
[9]
Morita, K.; Sasaki, H.; Fujimoto, K.; Furuse, M.; Tsukita, S. Claudin-11/OSP-based tight junctions of myelin sheaths in brain and Sertoli cells in testis. J. Cell. Biol.？1999, 145, 579–588.
[10]
Vogelmann, R.; Amieva, M.R.; Falkow, S.; Nelson, W.J. Breaking into the epithelial apical-junctional complex—news from pathogen hackers. Curr. Opin. Cell Biol.？2004, 16, 86–93.
[11]
Turner, J.R. Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application. Am. J. Pathol.？2006, 169, 1901–1909.
[12]
Guttman, J.A.; Finlay, B.B. Tight junctions as targets of infectious agents. Biochim. Biophys. Acta？2009, 1788, 832–841.
[13]
Ruiz, M. Wikipedia Commons, 2006. Available online: http://commons.wikimedia.org/wiki/File:Cellular_tight_junction_en.svg (Accessed on 22 April 2010).
[14]
Daugherty, B.L.; Ward, C.; Smith, T.; Ritzenthaler, J.D.; Koval, M. Regulation of heterotypic claudin compatibility. J. Biol. Chem.？2007, 282, 30005–30013.
[15]
Colegio, O.R.; Van Itallie, C.; Rahner, C.; Anderson, J.M. Claudin extracellular domains determine paracellular charge selectivity and resistance but not tight junction fibril architecture. Am. J. Physiol. Cell Physiol.？2003, 284, C1346–C1354.
[16]
Van Itallie, C.M.; Anderson, J.M. Claudins and epithelial paracellular transport. Annu. Rev. Physiol.？2006, 68, 403–429.
[17]
Umeda, K.; Ikenouchi, J.; Katahira-Tayama, S.; Furuse, K.; Sasaki, H.; Nakayama, M.; Matsui, T.; Tsukita, S.; Furuse, M. ZO-1 and ZO-2 independently determine where claudins are polymerized in tight-junction strand formation. Cell？2006, 126, 741–754.
[18]
Utech, M.; Ivanov, A.I.; Samarin, S.N.; Bruewer, M.; Turner, J.R.; Mrsny, R.J.; Parkos, C.A.; Nusrat, A. Mechanism of ifn-gamma-induced endocytosis of tight junction proteins: myosin II-dependent vacuolarization of the apical plasma membrane. Mol. Biol. Cell.？2005, 16, 5040–5052.
[19]
Van Itallie, C.M.; Fanning, A.S.; Bridges, A.; Anderson, J.M. ZO-1 stabilizes the tight junction solute barrier through coupling to the perijunctional cytoskeleton. Mol. Biol. Cell.？2009, 20, 3930–3940.
Alexandre, M.D.; Jeansonne, B.G.; Renegar, R.H.; Tatum, R.; Chen, Y.H. The first extracellular domain of claudin-7 affects paracellular Cl- permeability. Biochem. Biophys. Res. Commun.？2007, 357, 87–91.
[22]
Amasheh, S.; Meiri, N.; Gitter, A.H.; Schoneberg, T.; Mankertz, J.; Schulzke, J.D.; Fromm, M. Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells. J. Cell Sci.？2002, 115, 4969–4976.
[23]
Hou, J.; Paul, D.L.; Goodenough, D.A. Paracellin-1 and the modulation of ion selectivity of tight junctions. J. Cell Sci.？2005, 118, 5109–5118.
[24]
Van Itallie, C.M.; Rogan, S.; Yu, A.; Vidal, L.S.; Holmes, J.; Anderson, J.M. Two splice variants of claudin-10 in the kidney create paracellular pores with different ion selectivities. Am. J. Physiol. Renal Physiol.？2006, 291, F1288–F1299.
[25]
Piontek, J.; Winkler, L.; Wolburg, H.; Muller, S.L.; Zuleger, N.; Piehl, C.; Wiesner, B.; Krause, G.; Blasig, I.E. Formation of tight junction: determinants of homophilic interaction between classic claudins. FASEB J.？2008, 22, 146–158.
[26]
Wieckowski, E.U.; Wnek, A.P.; McClane, B.A. Evidence that an approximately 50-kDa mammalian plasma membrane protein with receptor-like properties mediates the amphiphilicity of specifically bound Clostridium perfringens enterotoxin. J. Biol. Chem.？1994, 269, 10838–10848.
[27]
McClane, B.A.; Chakrabarti, G. New insights into the cytotoxic mechanisms of Clostridium perfringens enterotoxin. Anaerobe？2004, 10, 107–114.
[28]
Fujita, K.; Katahira, J.; Horiguchi, Y.; Sonoda, N.; Furuse, M.; Tsukita, S. Clostridium perfringens enterotoxin binds to the second extracellular loop of claudin-3, a tight junction integral membrane protein. FEBS Lett.？2000, 476, 258–261.
[29]
Sonoda, N.; Furuse, M.; Sasaki, H.; Yonemura, S.; Katahira, J.; Horiguchi, Y.; Tsukita, S. Clostridium perfringens enterotoxin fragment removes specific claudins from tight junction strands: Evidence for direct involvement of claudins in tight junction barrier. J. Cell Biol.？1999, 147, 195–204.
[30]
Lohrberg, D.; Krause, E.; Schumann, M.; Piontek, J.; Winkler, L.; Blasig, I.E.; Haseloff, R.F. A strategy for enrichment of claudins based on their affinity to Clostridium perfringens enterotoxin. BMC Mol. Biol.？2009, 10, 61.
[31]
Mitic, L.L.; Unger, V.M.; Anderson, J.M. Expression, solubilization, and biochemical characterization of the tight junction transmembrane protein claudin-4. Protein Sci.？2003, 12, 218–227.
[32]
Winkler, L.; Gehring, C.; Wenzel, A.; Muller, S.L.; Piehl, C.; Krause, G.; Blasig, I.E.; Piontek, J. Molecular determinants of the interaction between Clostridium perfringens enterotoxin fragments and claudin-3. J. Biol. Chem.？2009, 284, 18863–18872.
[33]
Robertson, S.L.; Smedley, J.G., III; Singh, U.; Chakrabarti, G.; Van Itallie, C.M.; Anderson, J.M.; McClane, B.A. Compositional and stoichiometric analysis of Clostridium perfringens enterotoxin complexes in Caco-2 cells and claudin 4 fibroblast transfectants. Cell Microbiol.？2007, 9, 2734–2755, doi:10.1111/j.1462-5822.2007.00994.x. 17587331
[34]
Hardy, S.P.; Denmead, M.; Parekh, N.; Granum, P.E. Cationic currents induced by Clostridium perfringens type A enterotoxin in human intestinal CaCO-2 cells. J. Med. Microbiol.？1999, 48, 235–243.
[35]
Chakrabarti, G.; McClane, B.A. The importance of calcium influx, calpain and calmodulin for the activation of CaCo-2 cell death pathways by Clostridium perfringens enterotoxin. Cell Microbiol.？2005, 7, 129–146.
[36]
Chakrabarti, G.; Zhou, X.; McClane, B.A. Death pathways activated in CaCo-2 cells by Clostridium perfringens enterotoxin. Infect. Immun.？2003, 71, 4260–4270.
[37]
Smedley, J.G., III; Uzal, F.A.; McClane, B.A. Identification of a prepore large-complex stage in the mechanism of action of Clostridium perfringens enterotoxin. Infect. Immun.？2007, 75, 2381–2390, doi:10.1128/IAI.01737-06. 17307943
[38]
Geny, B.; Popoff, M.R. Bacterial protein toxins and lipids: pore formation or toxin entry into cells. Biol. Cell？2006, 98, 667–678.
[39]
Caserta, J.A.; Hale, M.L.; Popoff, M.R.; Stiles, B.G.; McClane, B.A. Evidence that membrane rafts are not required for the action of Clostridium perfringens enterotoxin. Infect. Immun.？2008, 76, 5677–5685.
[40]
Singh, U.; Van Itallie, C.M.; Mitic, L.L.; Anderson, J.M.; McClane, B.A. CaCo-2 cells treated with Clostridium perfringens enterotoxin form multiple large complex species, one of which contains the tight junction protein occludin. J. Biol. Chem.？2000, 275, 18407–18417.
[41]
Ivanov, A.I.; Nusrat, A.; Parkos, C.A. Endocytosis of Epithelial Apical Junctional Proteins by a Clathrin-Mediated Pathway into a Unique Storage Compartment. Mol. Biol. Cell.？2004, 15, 176–188.
[42]
Daugherty, B.L.; Mateescu, M.; Patel, A.S.; Wade, K.; Kimura, S.; Gonzales, L.W.; Guttentag, S.; Ballard, P.L.; Koval, M. Developmental regulation of claudin localization by fetal alveolar epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol.？2004, 287, L1266–L1273.
Kimura, J.; Abe, H.; Kamitani, S.; Toshima, H.; Fukui, A.; Miyake, M.; Kamata, Y.; Sugita-Konishi, Y.; Yamamoto, S.; Horiguchi, Y. Clostridium perfringens enterotoxin interacts with claudins via electrostatic attraction. J. Biol. Chem.？2010, 285, 401–408.
[45]
Holmes, J.L.; Van Itallie, C.M.; Rasmussen, J.E.; Anderson, J.M. Claudin profiling in the mouse during postnatal intestinal development and along the gastrointestinal tract reveals complex expression patterns. Gene Expr. Patterns？2006, 6, 581–588.
[46]
Fujita, H.; Chiba, H.; Yokozaki, H.; Sakai, N.; Sugimoto, K.; Wada, T.; Kojima, T.; Yamashita, T.; Sawada, N. Differential expression and subcellular localization of claudin-7, -8, -12, -13, and -15 along the mouse intestine. J. Histochem. Cytochem.？2006, 54, 933–944.
[47]
Van Itallie, C.M.; Betts, L.; Smedley, J.G., III; McClane, B.A.; Anderson, J.M. Structure of the claudin-binding domain of Clostridium perfringens enterotoxin. J. Biol. Chem.？2008, 283, 268–274. 17977833
Hanna, P.C.; Wnek, A.P.; McClane, B.A. Molecular cloning of the 3' half of the Clostridium perfringens enterotoxin gene and demonstration that this region encodes receptor-binding activity. J. Bacteriol.？1989, 171, 6815–6820.
[51]
Granum, P.E.; Richardson, M. Chymotrypsin treatment increases the activity of Clostridium perfringens enterotoxin. Toxicon？1991, 29, 898–900.
[52]
Kokai-Kun, J.F.; Benton, K.; Wieckowski, E.U.; McClane, B.A. Identification of a Clostridium perfringens enterotoxin region required for large complex formation and cytotoxicity by random mutagenesis. Infect. Immun.？1999, 67, 5634–5641.
[53]
Hanna, P.C.; Mietzner, T.A.; Schoolnik, G.K.; McClane, B.A. Localization of the receptor-binding region of Clostridium perfringens enterotoxin utilizing cloned toxin fragments and synthetic peptides. The 30 C-terminal amino acids define a functional binding region. J. Biol. Chem.？1991, 266, 11037–11043. 1645721
[54]
McClane, B.A. An overview of Clostridium perfringens enterotoxin. Toxicon？1996, 34, 1335–1343.
[55]
Ebihara, C.; Kondoh, M.; Harada, M.; Fujii, M.; Mizuguchi, H.; Tsunoda, S.; Horiguchi, Y.; Yagi, K.; Watanabe, Y. Role of Tyr306 in the C-terminal fragment of Clostridium perfringens enterotoxin for modulation of tight junction. Biochem. Pharmacol.？2007, 73, 824–830.
[56]
Harada, M.; Kondoh, M.; Ebihara, C.; Takahashi, A.; Komiya, E.; Fujii, M.; Mizuguchi, H.; Tsunoda, S.; Horiguchi, Y.; Yagi, K.; Watanabe, Y. Role of tyrosine residues in modulation of claudin-4 by the C-terminal fragment of Clostridium perfringens enterotoxin. Biochem. Pharmacol.？2007, 73, 206–214.
[57]
Robertson, S.L.; Smedley, J.G., III; McClane, B.A. Identification of a claudin-4 residue important for mediating the host cell binding and action of Clostridium perfringens enterotoxin. Infect. Immun.？2010, 78, 505–517, doi:10.1128/IAI.00778-09. 19884339
[58]
Wray, C.; Mao, Y.; Pan, J.; Chandrasena, A.; Piasta, F.; Frank, J.A. Claudin-4 augments alveolar epithelial barrier function and is induced in acute lung injury. Am. J. Physiol. Lung Cell Mol. Physiol.？2009, 297, L219–L227, doi:10.1152/ajplung.00043.2009.
[59]
Koval, M. Tight junctions, but not too tight: fine control of lung permeability by claudins. Am. J. Physiol. Lung Cell Mol. Physiol.？2009, 297, L217–L218.
[60]
Wang, F.; Daugherty, B.; Keise, L.L.; Wei, Z.; Foley, J.P.; Savani, R.C.; Koval, M. Heterogeneity of claudin expression by alveolar epithelial cells. Am. J. Respir. Cell Mol. Biol.？2003, 29, 62–70.
[61]
Fernandez, A.L.; Koval, M.; Fan, X.; Guidot, D.M. Chronic alcohol ingestion alters claudin expression in the alveolar epithelium of rats. Alcohol？2007, 41, 371–379.
[62]
Kominsky, S.L. Claudins: emerging targets for cancer therapy. Expert Rev. Mol. Med.？2006, 8, 1–11.
[63]
Ouban, A.; Ahmed, A.A. Claudins in human cancer: a review. Histol. Histopathol.？2010, 25, 83–90.
[64]
Hewitt, K.J.; Agarwal, R.; Morin, P.J. The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer？2006, 6, 186.
[65]
Soler, A.P.; Laughlin, K.V.; Mullin, J.M. Effects of epidermal growth factor versus phorbol ester on kidney epithelial (LLC-PK1) tight junction permeability and cell division. Exp. Cell Res.？1993, 207, 398–406.
[66]
Soler, A.P.; Miller, R.D.; Laughlin, K.V.; Carp, N.Z.; Klurfeld, D.M.; Mullin, J.M. Increased tight junctional permeability is associated with the development of colon cancer. Carcinogenesis？1999, 20, 1425–1431.
[67]
Ikenouchi, J.; Matsuda, M.; Furuse, M.; Tsukita, S. Regulation of tight junctions during the epithelium-mesenchyme transition: direct repression of the gene expression of claudins/occludin by Snail. J. Cell Sci.？2003, 116, 1959–1967.
[68]
Kominsky, S.L.; Argani, P.; Korz, D.; Evron, E.; Raman, V.; Garrett, E.; Rein, A.; Sauter, G.; Kallioniemi, O.P.; Sukumar, S. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene？2003, 22, 2021–2033.
[69]
Kramer, F.; White, K.; Kubbies, M.; Swisshelm, K.; Weber, B.H. Genomic organization of claudin-1 and its assessment in hereditary and sporadic breast cancer. Hum. Genet.？2000, 107, 249–256.
[70]
Al Moustafa, A.E.; Alaoui-Jamali, M.A.; Batist, G.; Hernandez-Perez, M.; Serruya, C.; Alpert, L.; Black, M.J.; Sladek, R.; Foulkes, W.D. Identification of genes associated with head and neck carcinogenesis by cDNA microarray comparison between matched primary normal epithelial and squamous carcinoma cells. Oncogene？2002, 21, 2634–2640.
[71]
Soini, Y. Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of tumours. Histopathology？2005, 46, 551–560, doi:10.1111/j.1365-2559.2005.02127.x. 15842637
[72]
Tokes, A.M.; Kulka, J.; Paku, S.; Szik, A.; Paska, C.; Novak, P.K.; Szilak, L.; Kiss, A.; Bogi, K.; Schaff, Z. Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res.？2005, 7, R296–R305.
[73]
Lee, S.K.; Moon, J.; Park, S.W.; Song, S.Y.; Chung, J.B.; Kang, J.K. Loss of the tight junction protein claudin 4 correlates with histological growth-pattern and differentiation in advanced gastric adenocarcinoma. Oncol. Rep.？2005, 13, 193–199.
[74]
Swisshelm, K.; Machl, A.; Planitzer, S.; Robertson, R.; Kubbies, M.; Hosier, S. SEMP1, a senescence-associated cDNA isolated from human mammary epithelial cells, is a member of an epithelial membrane protein superfamily. Gene？1999, 226, 285–295.
[75]
Johnson, A.H.; Frierson, H.F.; Zaika, A.; Powell, S.M.; Roche, J.; Crowe, S.; Moskaluk, C.A.; El-Rifai, W. Expression of tight-junction protein claudin-7 is an early event in gastric tumorigenesis. Am. J. Pathol.？2005, 167, 577–584.
[76]
Liebner, S.; Fischmann, A.; Rascher, G.; Duffner, F.; Grote, E.H.; Kalbacher, H.; Wolburg, H. Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol.？2000, 100, 323–331.
[77]
Cohn, M.L.; Goncharuk, V.N.; Diwan, A.H.; Zhang, P.S.; Shen, S.S.; Prieto, V.G. Loss of claudin-1 expression in tumor-associated vessels correlates with acquisition of metastatic phenotype in melanocytic neoplasms. J. Cutan. Pathol.？2005, 32, 533–536.
[78]
Kominsky, S.L.; Vali, M.; Korz, D.; Gabig, T.G.; Weitzman, S.A.; Argani, P.; Sukumar, S. Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. Am. J. Pathol.？2004, 164, 1627–1633.
[79]
Rangel, L.B.; Sherman-Baust, C.A.; Wernyj, R.P.; Schwartz, D.R.; Cho, K.R.; Morin, P.J. Characterization of novel human ovarian cancer-specific transcripts (HOSTs) identified by serial analysis of gene expression. Oncogene？2003, 22, 7225–7232.
[80]
Long, H.; Crean, C.D.; Lee, W.H.; Cummings, O.W.; Gabig, T.G. Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer Res.？2001, 61, 7878–7881.
[81]
Agarwal, R.; D'Souza, T.; Morin, P.J. Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res.？2005, 65, 7378–7385.
[82]
Michl, P.; Barth, C.; Buchholz, M.; Lerch, M.M.; Rolke, M.; Holzmann, K.H.; Menke, A.; Fensterer, H.; Giehl, K.; Lohr, M.; Leder, G.; Iwamura, T.; Adler, G.; Gress, T.M. Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer. Cancer Res.？2003, 63, 6265–6271.
[83]
Morin, P.J. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res.？2005, 65, 9603–9606.
[84]
Montgomery, E.; Mamelak, A.J.; Gibson, M.; Maitra, A.; Sheikh, S.; Amr, S.S.; Yang, S.; Brock, M.; Forastiere, A.; Zhang, S.; Murphy, K.M.; Berg, K.D. Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions. Appl. Immunohistochem. Mol. Morphol.？2006, 14, 24–30.
[85]
Cunningham, S.C.; Kamangar, F.; Kim, M.P.; Hammoud, S.; Haque, R.; Iacobuzio-Donahue, C.A.; Maitra, A.; Ashfaq, R.; Hustinx, S.; Heitmiller, R.E.; Choti, M.A.; Lillemoe, K.D.; Cameron, J.L.; Yeo, C.J.; Schulick, R.D.; Montgomery, E. Claudin-4, mitogen-activated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions. Cancer Epidemiol. Biomarkers Prev.？2006, 15, 281–287.
[86]
Michl, P.; Buchholz, M.; Rolke, M.; Kunsch, S.; Lohr, M.; McClane, B.; Tsukita, S.; Leder, G.; Adler, G.; Gress, T.M. Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology？2001, 121, 678–684.
[87]
Santin, A.D.; Cane, S.; Bellone, S.; Palmieri, M.; Siegel, E.R.; Thomas, M.; Roman, J.J.; Burnett, A.; Cannon, M.J.; Pecorelli, S. Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer Res.？2005, 65, 4334–4342. 15899825
[88]
Kominsky, S.L.; Tyler, B.; Sosnowski, J.; Brady, K.; Doucet, M.; Nell, D.; Smedley, J.G., III; McClane, B.; Brem, H.; Sukumar, S. Clostridium perfringens enterotoxin as a novel-targeted therapeutic for brain metastasis. Cancer Res.？2007, 67, 7977–7982. 17804705
[89]
Ebihara, C.; Kondoh, M.; Hasuike, N.; Harada, M.; Mizuguchi, H.; Horiguchi, Y.; Fujii, M.; Watanabe, Y. Preparation of a claudin-targeting molecule using a C-terminal fragment of Clostridium perfringens enterotoxin. J. Pharmacol. Exp. Ther.？2006, 316, 255–260.
[90]
Yuan, X.; Lin, X.; Manorek, G.; Kanatani, I.; Cheung, L.H.; Rosenblum, M.G.; Howell, S.B. Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors. Mol. Cancer Ther.？2009, 8, 1906–1915.
[91]
Litkouhi, B.; Kwong, J.; Lo, C.M.; Smedley, J.G., III; McClane, B.A.; Aponte, M.; Gao, Z.; Sarno, J.L.; Hinners, J.; Welch, W.R.; Berkowitz, R.S.; Mok, S.C.; Garner, E.I. Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin. Neoplasia？2007, 9, 304–314, doi:10.1593/neo.07118. 17460774
[92]
Saeki, R.; Kondoh, M.; Kakutani, H.; Tsunoda, S.; Mochizuki, Y.; Hamakubo, T.; Tsutsumi, Y.; Horiguchi, Y.; Yagi, K. A novel tumor-targeted therapy using a claudin-4-targeting molecule. Mol. Pharmacol.？2009, 76, 918–926.
[93]
Ogata, M.; Chaudhary, V.K.; Pastan, I.; FitzGerald, D.J. Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol. J. Biol. Chem.？1990, 265, 20678–20685.
[94]
Saeki, R.; Kondoh, M.; Kakutani, H.; Matsuhisa, K.; Takahashi, A.; Suzuki, H.; Kakamu, Y.; Watari, A.; Yagi, K. A claudin-targeting molecule as an inhibitor of tumor metastasis. J. Pharmacol. Exp. Ther.？2010.
[95]
Kondoh, M.; Masuyama, A.; Takahashi, A.; Asano, N.; Mizuguchi, H.; Koizumi, N.; Fujii, M.; Hayakawa, T.; Horiguchi, Y.; Watanbe, Y. A novel strategy for the enhancement of drug absorption using a claudin modulator. Mol. Pharmacol.？2005, 67, 749–756.
[96]
Sugahara, K.N.; Teesalu, T.; Karmali, P.P.; Kotamraju, V.R.; Agemy, L.; Greenwald, D.R.; Ruoslahti, E. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science？2010, 328, 1031–1035.
[97]
Wallace, F.M.; Mach, A.S.; Keller, A.M.; Lindsay, J.A. Evidence for Clostridium perfringens enterotoxin (CPE) inducing a mitogenic and cytokine response in vitro and a cytokine response in vivo. Curr. Microbiol.？1999, 38, 96–100.
[98]
Nagata, K.; Okamura, H.; Kunitoh, D.; Uemura, T. Mitogenic activity of Clostridium perfringens enterotoxin in human peripheral lymphocytes. J. Vet. Med. Sci.？1997, 59, 5–8.
[99]
Bowness, P.; Moss, P.A.; Tranter, H.; Bell, J.I.; McMichael, A.J. Clostridium perfringens enterotoxin is a superantigen reactive with human T cell receptors V beta 6.9 and V beta 22. J. Exp. Med.？1992, 176, 893–896.
[100]
Krakauer, T.; Fleischer, B.; Stevens, D.L.; McClane, B.A.; Stiles, B.G. Clostridium perfringens enterotoxin lacks superantigenic activity but induces an interleukin-6 response from human peripheral blood mononuclear cells. Infect. Immun.？1997, 65, 3485–3488.
